We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CYBIN

News List

Cybin Announces Overnight Marketed Public Offering of Common Shares firstwordpharma
July 28, 2021
Cybin Inc. is pleased to announce that it has launched an overnight marketed public offering of common shares in the capital of the Company (the "Shares") at a price per Share and for aggregate gross proceeds to be determined in the context of the market.
Cybin to Leverage Catalent’s Zydis for Psychiatric Drug contractpharma
March 23, 2021
To apply Zydis orally disintegrating tablet (ODT) technology for delivery of Cybin’s potential therapy for treatment-resistant psychiatric disorders.
CYBIN signs agreement to acquire Adelia Therapeutics pharmaceutical-business-review
December 10, 2020
Cybin announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CDN$20,161,575 (approximately $15.75m) in an all-stock transaction.